Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 8/20 | 0.49 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1475075 | 0.89 | MAPKAPK5 (0.60) | MAPKAPK5TTKCDK4CCNA2CCND1 | |
| SCHEMBL1476829 | 0.86 | MAPKAPK5 (0.69) | MAPKAPK5PIP4K2AACVR1 | |
| SCHEMBL1476114 | 0.83 | MAPKAPK5 (0.49) | MAPKAPK5CDK4CCND1CDK2ACVR1 | |
| SCHEMBL1477008 | 0.81 | MAPKAPK5 (0.72) | MAPKAPK5FYN | |
| SCHEMBL2394082 | 0.80 | MAPKAPK5 (0.47) | MAPKAPK5TTK | |
| SCHEMBL1476537 | 0.79 | PIP4K2A (0.46) | MAPKAPK5PIP4K2ACD38CDK4CCNA2 | |
| SCHEMBL12443601 | 0.75 | MAPKAPK5 (0.72) | MAPKAPK5PIP4K2AACVR1 | |
| SCHEMBL1475077 | 0.74 | MAPKAPK5 (0.81) | MAPKAPK5TTKCDK4CCND1CDK2 | |
| SCHEMBL12515268 | 0.74 | MAPKAPK5 (0.59) | MAPKAPK5TTKCDK4CCNA2CCND1 | |
| SCHEMBL2390006 | 0.74 | MAPKAPK5 (0.41) | MAPKAPK5TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-11-25 | — | — | US | disclosed |
| EP-2029602-B1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-04-21 | — | — | EP | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-2029602-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | PTGES, IL1B, PTGER1 | MAPKAPK5 5/4885PIP4K2A 765/4885CD38 3519/4885 |
| US-20100298300-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | P2RX5, P2RX3, IL1B | MAPKAPK5 18/4885PIP4K2A 881/4885CD38 1565/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | MAPKAPK5 18/4885PIP4K2A 881/4885CD38 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.